What Is Heart Failure?
Heart failure (congestive heart failure) is a clinical syndrome of fluid overload or inadequate tissue perfusion. It signals myocardial disease with a problem in contraction (systolic dysfunction) or filling (diastolic dysfunction) that may or may not cause pulmonary or systemic congestion. It is usually a progressive, lifelong condition managed with lifestyle changes and medications to prevent episodes of acute decompensation.
Classification
Heart failure is left-sided or right-sided. In left-sided (left ventricular) failure, the left ventricle cannot pump blood effectively into the aorta and systemic circulation. Pulmonary venous volume and pressure rise, forcing fluid from the pulmonary capillaries into the tissues and alveoli, causing pulmonary interstitial edema and impaired gas exchange. In right-sided failure, congestion predominates in the peripheral tissues and viscera: the right ventricle cannot eject blood or accommodate all the venous return, so venous pressure rises, producing JVD and increased capillary hydrostatic pressure throughout the venous system.
The 2022 ACC/AHA/HFSA guideline stages heart failure and now labels Stage A "at risk" and Stage B "pre-HF" to emphasize prevention:
- Stage A (at risk): high risk for HF but no structural heart disease, biomarkers, or symptoms.
- Stage B (pre-HF): structural heart disease or abnormal biomarkers without current or prior HF symptoms.
- Stage C: left ventricular dysfunction or structural heart disease with current or prior symptoms.
- Stage D: refractory end-stage heart failure requiring specialized interventions.
Pathophysiology
Heart failure follows cardiovascular conditions such as chronic hypertension, coronary artery disease, and valvular disease. As it develops, the body activates neurohormonal compensation. Systolic HF reduces the blood volume ejected from the ventricle. The sympathetic nervous system releases epinephrine and norepinephrine. Decreased renal perfusion triggers renin release, which promotes angiotensin I; ACE converts angiotensin I to angiotensin II, which constricts vessels and stimulates aldosterone release, causing sodium and fluid retention. Muscle fiber contractility falls as the workload rises, and the heart compensates by thickening the heart muscle.
Statistics
Like coronary artery disease, the incidence of HF rises with age. About 6.7 million U.S. adults over age 20 have HF, and roughly 1 in 4 people will develop it in their lifetime, per the Heart Failure Society of America HF Stats 2024 report; prevalence is projected to reach 8.7 million by 2030. It is most common in people older than 75 years and is now considered epidemic in the United States. HF is the most common reason for hospitalization in people older than 65 years and the second most common reason for office visits. The estimated economic burden is more than $33 billion annually in direct and indirect costs and is still expected to rise.
HF affects both women and men, though mortality is higher among women. Death rates are higher in African Americans than in non-Hispanic whites at all ages. It is primarily a disease of older adults, affecting 6% to 10% of those older than 65, and is the leading cause of hospitalization in older people.
Causes
Atherosclerosis of the coronary arteries is the primary cause; coronary artery disease is found in more than 60% of HF patients. Ischemia deprives heart cells of oxygen and leads to acidosis from lactic acid accumulation. HF from cardiomyopathy is usually chronic and progressive. Systemic or pulmonary hypertension raises afterload, increasing the workload and causing hypertrophy of myocardial fibers. Valvular disease makes forward blood flow harder, raising intracardiac pressure and cardiac workload.
Clinical Manifestations
The manifestations of different HF types are similar, so they do not distinguish the types, but they track with the ventricle affected.
In left-sided HF, dyspnea may be triggered by minimal to moderate activity. The cough is initially dry and nonproductive. Bibasilar crackles appear early and, as it worsens, can be heard across all lung fields. Oxygen saturation may fall from increased pulmonary pressures.
In right-sided HF, the liver enlarges from venous engorgement, fluid accumulates in the peritoneal cavity and presses on the stomach and intestines (GI distress), and appetite drops from venous engorgement and stasis in the abdominal organs.
Prevention
Prevention is mostly lifestyle. Avoiding fatty and salty foods improves cardiovascular health. Cardiovascular exercise three times a week keeps the system running. Smoking cessation matters because nicotine causes vasoconstriction that raises vessel pressure.
Complications
Most HF therapy problems relate to diuretics. Excessive, repeated diuresis can cause hypokalemia, while ACE inhibitors, ARBs, or spironolactone can cause hyperkalemia. Prolonged diuretic therapy can cause hyponatremia, leading to disorientation, fatigue, apprehension, weakness, and muscle cramps. Volume depletion from excessive fluid loss can cause dehydration and hypotension.
Assessment and Diagnostic Findings
HF may go undetected until pulmonary and peripheral edema appear. The ECG may show hypertrophy, axis deviation, ischemia, damage patterns, dysrhythmias, and ST-T abnormalities. Chest x-ray may show an enlarged cardiac shadow or an abnormal contour suggesting ventricular aneurysm. Echocardiography (including Doppler and transesophageal) reveals chamber dimensions, valvular function and structure, and ventricular dilation and dysfunction. A MUGA heart scan measures cardiac volume, ejection fraction, and wall motion. Exercise or pharmacologic stress myocardial perfusion detects ischemia and wall motion abnormalities, and PET is a sensitive test for ischemia and viability. Cardiac catheterization assesses pressures, differentiates right- from left-sided failure, and evaluates coronary artery patency. Supporting labs include liver enzymes (elevated in liver congestion), digoxin and other cardiac drug levels (therapeutic range), bleeding and clotting times, electrolytes, pulse oximetry, ABGs, BUN/creatinine, serum albumin and transferrin, CBC, ESR, and thyroid studies.
Medical Management
The goals are to relieve symptoms, improve functional status and quality of life, and extend survival.
Pharmacologic therapy: ACE inhibitors slow HF progression, improve exercise tolerance, reduce hospitalizations, and promote vasodilation and diuresis by lowering afterload and preload. ARBs block angiotensin I conversion at the angiotensin II receptor, lowering blood pressure and systemic vascular resistance and improving cardiac output. Beta blockers reduce the harm of constant sympathetic stimulation. Diuretics remove excess extracellular fluid by increasing urine output in patients with fluid overload. Calcium channel blockers cause vasodilation and reduce systemic vascular resistance but are contraindicated in systolic HF.
Nutritional therapy: a low-sodium diet of 2 to 3 g/day reduces fluid retention, eases peripheral and pulmonary congestion, and lowers circulating volume and myocardial work. Compliance matters, since dietary indiscretion can drive severe exacerbations requiring hospitalization.
Additional therapy: supplemental oxygen is based on the degree of pulmonary congestion and hypoxia. Cardiac resynchronization therapy uses a biventricular pacemaker for electrical conduction defects. Ultrafiltration is an option for severe fluid overload. Cardiac transplant is the only option for long-term survival in some patients with end-stage disease.
Nursing Management
Despite treatment advances, HF morbidity and mortality remain high, and nurses have a major impact on outcomes through assessment, volume monitoring, medication management, and patient teaching.
Frequently Asked Questions
What is the difference between left-sided and right-sided heart failure? Left-sided failure backs fluid up into the lungs, producing crackles, dyspnea, and pulmonary edema. Right-sided failure backs fluid up into the body, producing JVD, peripheral edema, and hepatomegaly. Left-sided failure is the most common cause of right-sided failure.
What are the ACC/AHA stages of heart failure? Stage A is "at risk" with no structural disease, Stage B is "pre-HF" with structural change but no symptoms, Stage C is symptomatic structural disease, and Stage D is advanced, refractory disease. The 2022 guideline renamed Stages A and B to stress prevention.
What is the most common cause of heart failure? Coronary artery disease, found in more than 60% of patients. Chronic hypertension, valvular disease, and cardiomyopathy are other major contributors.
What are the early signs of decompensation to watch for? A weight gain of 2 to 3 pounds in a day or about 5 pounds in a week, worsening dyspnea, new orthopnea, rising fatigue, and falling exercise tolerance. Daily weights catch fluid retention before crackles do.
Why do heart failure patients get ACE inhibitors and beta blockers? These drugs interrupt the neurohormonal cycle (renin-angiotensin-aldosterone and sympathetic activation) that drives remodeling. They are guideline-directed therapy that reduces hospitalization and mortality, not just symptom relief.
How common is heart failure in the United States? About 6.7 million U.S. adults have it, and roughly 1 in 4 people will develop it in their lifetime, per the Heart Failure Society of America HF Stats 2024 report.